Anti-Mouse CXCL9 [MIG-2F5-5] In Vivo Antibody - Low Endotoxin
Introducing the Anti-Mouse CXCL9/MIG [2F5-5] In Vivo Antibody - Low Endotoxin from Assay Genie, a highly specific monoclonal antibody designed for in vivo applications. This antibody targets the CXCL9 (MIG) protein, a key chemokine involved in immune cell recruitment and T-cell trafficking, making it ideal for research in immunology and inflammation-related fields. With a rat IgG2a isotype, it ensures high purity and low endotoxin levels (<1.0 EU/mg), perfect for ELISA, flow cytometry, immunohistochemistry, and other assays.
Available in various sizes, it is formulated in phosphate-buffered saline for stability and efficacy. Enhance your research with this reliable and versatile antibody. CXCL9 (MIG) is a member of the CXC chemokine family and is expressed in response to interferon-gamma. It plays a significant role in the immune system by directing the migration of monocytes, neutrophils, and other immune cells toward sites of inflammation.
Product Name:
Anti-Mouse CXCL9 (Clone MIG-2F5-5) In Vivo Antibody - Low Endotoxin
Product Code:
IVMB0274
Size:
1 mg, 5 mg, 25 mg, 50 mg, 100 mg
Clone:
MIG-2F5-5
Protein:
CXCR3
Product Type:
Monoclonal Antibody
Synonyms:
MIG-1, MIG
Isotype:
IgG
Reactivity:
Mouse
Applications:
FC, IF, In Vivo, N
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Endotoxin Level:
< 1.0 EU/mg as determined by the LAL method
Purity:
≥95% monomer by analytical SEC â‹… >95% by SDS Page
Product Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Applications:
FC, IF, In Vivo, N
Reactivity:
Mouse
Host Species:
Armenian Hamster
Specificity:
MIG-2F5-5 activity is directed against murine CXCL9 (monokine induced by gamma interferon, MIG).
Antigen Distribution:
CXCL9 is mainly secreted by macrophages, monocytes, endothelial cells, fibroblasts, and cancer cells in response to IFN-gamma and is also expressed in intratumoral dendritic cells.
Immunogen:
Mouse plasmacytoid dendritic cells
Concentration:
≥ 5.0 mg/ml
Endotoxin Level:
< 1.0 EU/mg as determined by the LAL method
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Purity:
≥95% monomer by analytical SEC â‹… >95% by SDS Page
Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -70°C. Avoid Repeated Freeze Thaw Cycles.
CXCL9 is a chemokine, which are small 8-15 kDa proteins that function in immune responses1. CXCL9, -10, -11 and their receptor CXCR3 regulate immune cell migration, differentiation, and activation, leading to tumor suppression in the paracrine axis. However, in the autocrine axis, they may be involved in tumor growth and metastasis. The CXCL9, -10, -11/CXCR3 axis also regulates differentiation of naïve T cells to T helper 1 (Th1) cells. CXCL9, -10, and -11 are usually expressed at low levels but are upregulated by cytokine stimulation. CXCL9 is dependent on IFNgamma for expression2. CXCL9 is also capable of direct antimicrobial activity against pathogen infection3. CXCL9 is secreted by macrophages4, monocytes, endothelial cells, fibroblasts, and cancer cells in response to IFN-gamma1 and is also expressed in intratumoral dendritic cells5. CXCL9 is also detectable in CD103+ conventional dendritic cells (cDCs) isolated from transgenic murine MMTV-PyMT tumors following in vivo administration of brefeldin A5. Additionally, CXCL9 is detectable in myeloid cells following ex vivo stimulation with IFN-gamma. Furthermore, CXCL9 expression is enhanced in CD8α+ cDC1s when anti-TIM-3 is added. Neutralizing antibodies against Galectin-9 lead to an increase in CXCL9 expression comparable to that induced by anti-TIM-3 antibody. Additionally, endothelial cell expression of CXCL9 is strongly increased in liver sinusoidal endothelial cells isolated from nonalcoholic steatohepatitis mouse livers6. MIG-2F5-5 was generated by immunizing male Armenian hamsters with recombinant murine CXCL9, and specificity was confirmed by ELISA7.
